ARTICLE | Product Development
For patients’ sake, collaborate already
Editor’s Commentary: How and where industry can collaborate on cancer immunotherapy platform trials
April 26, 2019 7:16 PM UTC
Cancer immunotherapy companies must stop squandering the most precious stakeholder, patients, and collaborate now on platform trials to test new combination regimens. A straightforward platform trial design that tests different combo partners with PD-1/PD-L1 agents could save companies time, money and get even greater advancements to patients faster.
Combination studies account for the largest portion of the thousands of ongoing PD-1/PD-L1 trials, as companies aim to gain a foothold in immuno-oncology or extend their franchise...
BCIQ Company Profiles